<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068193</url>
  </required_header>
  <id_info>
    <org_study_id>BR-RGR-CT-101</org_study_id>
    <nct_id>NCT05068193</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of &quot;BR2008&quot; With &quot;BR2008-1&quot; in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Two-way Crossover Study to Compare the Pharmacokinetics and Bioequivalence of &quot;BR2008&quot; With &quot;BR2008-1&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to compare the pharmacokinetics and bioequivalence of BR2008 with BR2008-1&#xD;
      in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">January 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0-120 hours after administration</time_frame>
    <description>Area under the plasma drug concentration-time curve from time 0 to time t of BR2008 and BR2008-1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-120 hours after administration</time_frame>
    <description>Maximum concentration of drug in plasma of BR2008 and BR2008-1</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.&#xD;
*Sequence 1&#xD;
[Period I] Administration of BR2008-1 (single dose)&#xD;
- Wash out for 2 weeks&#xD;
[Period II] Administration of BR2008 (single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.&#xD;
*Sequence 2&#xD;
[Period I] Administration of BR2008 (single dose)&#xD;
Wash out for 2 weeks&#xD;
[Period II] Administration of BR2008-1 (single dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR2008-1 (R)</intervention_name>
    <description>After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR2008 (T)</intervention_name>
    <description>After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        &lt;Inclusion Criteria&gt;&#xD;
&#xD;
          1. Healthy adults aged over 19 years at screening&#xD;
&#xD;
          2. Those who have no congenital or chronic diseases and have no abnormal symptoms or&#xD;
             findings based on medical examination results&#xD;
&#xD;
          3. Determined to be eligible subjects as a result of clinical laboratory tests and&#xD;
             electrocardiography performed according to this protocol at screening&#xD;
&#xD;
          4. Those who have calculated body mass index(BMI) within the range of 18.0 to 30.0 kg/m2&#xD;
&#xD;
          5. Those who do not have a history of the psychiatric diseases within the last 5 years&#xD;
             before screening&#xD;
&#xD;
          6. Those who do not have a history of gastrointestinal diseases (e.g., Crohn's disease,&#xD;
             ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (however,&#xD;
             simple appendectomy or hernia repair are excluded) that may affect the absorption of&#xD;
             drugs&#xD;
&#xD;
          7. Voluntarily decide to participate in the study and provide written consent to follow&#xD;
             the study directions after listening to and fully understanding the detailed&#xD;
             explanation on this study&#xD;
&#xD;
        &lt;Exclusion Criteria&gt;&#xD;
&#xD;
          1. Those who took drugs inducing and inhibiting drug-metabolizing enzymes, such as&#xD;
             barbital, within 30 days prior to the first administration date, or took any drugs&#xD;
             that may the clinical trial&#xD;
&#xD;
          2. Those who continue to drink alcohol (Male: &gt;5 units/week, Female: &gt;2.5 units/week)&#xD;
             within 1 month prior to the first administration date&#xD;
&#xD;
          3. Those who continue to smoke (&gt;10 cigarettes/day) or cannot stop smoking during&#xD;
             hospitalization throughout the entire period from the date of 48 hours before the&#xD;
             first administration of the investigational product to the last pharmacokinetic blood&#xD;
             sampling&#xD;
&#xD;
          4. Those who have been determined by the investigator to be ineligible to participate in&#xD;
             the clinical trial&#xD;
&#xD;
          5. Those who have participated in another clinical trial or bioequivalence test (the last&#xD;
             day of administration of the investigational product or bioequivalence test drug)&#xD;
             within 6 months prior to the first administration date&#xD;
&#xD;
          6. Those who have donated whole blood within 2 months, or donated blood components&#xD;
             (apheresis) within 2 weeks, or who have received a blood transfusion within 30 days&#xD;
             prior to screening&#xD;
&#xD;
          7. Those who do not agree to rule out the possibility of their and their spouses' or&#xD;
             sexual partners' pregnancy using a medically acceptable methods of contraception&#xD;
             throughout the entire period from the date of the first administration of the&#xD;
             investigational product to 8 weeks after the last administration of the&#xD;
             investigational product&#xD;
&#xD;
          8. Those with severe hepatic impairment, or any of the following results in the screening&#xD;
             tests&#xD;
&#xD;
               -  Total bilirubin ≥ 1.5 x ULN&#xD;
&#xD;
               -  AST(SGOT) or ALT(SGPT) ≥ 2 x ULN&#xD;
&#xD;
               -  r-GTP ≥ 1.5 x ULN&#xD;
&#xD;
          9. Those with severe renal impairment, or serum creatinine levels upper than 1.5 times of&#xD;
             ULN&#xD;
&#xD;
         10. Those with a predisposition to bleeding, or taking anticoagulants(Warfarin,&#xD;
             phenprocoumon), or taking concomitant medications that increase the risk of bleeding&#xD;
&#xD;
         11. Those with cardiovascular disease (heart ischemia and infarction)&#xD;
&#xD;
         12. Those with systolic blood pressure&lt;90mmHg or &gt;140mmHg, or diastolic blood pressure&#xD;
             &lt;60mmHg or &gt;90mmHg&#xD;
&#xD;
         13. Those who have hypersensitivity reactions to &quot;BR2008&quot; or &quot;BR2008-1&quot;&#xD;
&#xD;
         14. Pregnant woman, potentially pregnant woman, or breast-feeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bestian Hospital</name>
      <address>
        <city>Osong</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

